Viral vector vaccines by McCann, N, O'Connor, D, Lambe, T, Pollard, AJ

“…The development of new and effective vaccine technologies is vital in the fight against such threats. …”

Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom by Vanderslott, S, Emary, K, te Water Naude, R, English, M, Thomas, T, Patrick-Smith, M, Henry, J, Douglas, N, Moore, M, Stuart, A, Hodgson, SH, Pollard, AJ

“…<br><strong>Background</strong> Vaccine nationalism has become a key topic of discussion during the development, testing, and rollout of COVID-19 vaccines. …”

Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use by Hill, M, Bandyopadhyay, AS, Pollard, AJ

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children by Kazmin, D, Clutterbuck, EA, Napolitani, G, Wilkins, AL, Tarlton, A, Thompson, AJ, Montomoli, E, Lapini, G, Bihari, S, White, R, Jones, C, Snape, MD, Galal, U, Yu, L-M, Rappuoli, R, Del Giudice, G, Pollard, AJ, Pulendran, B

“…We analyzed transcriptional responses elicited by vaccination in peripheral blood, as well as cellular and antibody responses following primary and booster vaccinations. …”

The impact of infant Bacille Calmette-Guérin vaccination on the immunogenicity of other vaccines: a randomized exploratory study by Maytum, A, Porter, D, de Whalley, P, Thompson, A, Plested, E, Kerridge, S, Liu, X, Smits, G, van der Klis, F, Snape, MD, Clutterbuck, E, Pollard, AJ

“…The effect of the Bacille Calmette-Guérin (BCG) vaccine on the immunogenicity of separately administered serogroup C meningococcal vaccine and other vaccinations was examined in 28 infants randomized to receive BCG at age ≤7 days, at 3 months or after study completion. …”

Anamnestic immune response and safety of an inactivated quadrivalent influenza vaccine in primed versus vaccine-naïve children by Claeys, C, Chandrasekaran, V, García-Sicilia, J, Prymula, R, Díez-Domingo, J, Brzostek, J, Marès-Bermúdez, J, Martinón-Torres, F, Pollard, AJ, Růžková, R, Martinez, AC, Ulied, A, Valdivieso, MM, Faust, SN, Snape, MD, Friel, D, Ollinger, T, Soni, J, Schuind, A, Li, P, Innis, BL, Jain, VK

“…<strong>Background</strong>: It has not yet been demonstrated whether two doses of inactivated quadrivalent influenza vaccine (IIV4) prime a booster response in infants. …”

Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh by Khanam, F, Babu, G, Rahman, N, Liu, X, Rajib, NH, Ahmed, SU, Hossen, MI, Biswas, PK, Kelly, S, Thesis-Nyland, K, Mujadidi, Y, McMillan, NAJ, Pollard, AJ, Clemens, JD, Qadri, F

“…Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. …”

Vaccination against respiratory syncytial virus by Green, CA, Drysdale, SB, Pollard, AJ, Sande, CJ

“…A multitude of safe and immunogenic vaccine candidates have failed to induce the protective immunity needed for licensure, and in recent years this has included the largest clinical trials of RSV vaccines in history. …”

B cell response to pneumococcal vaccines by Trück, J

“…The inclusion of pneumococcal conjugate vaccines in routine infant immunisation programmes has had a major impact on disease rates. …”

Vaccine communication in a digital society by Thomas, TM, Pollard, AJ

Motivations for paediatric vaccine trial participation by Hillson, K, Kantor, J, Pinto, MV, Pollard, AJ, Kelly, D, Vanderslott, S

The collective voice of early phase COVID-19 vaccine trial participants: Insights for improving confidence in novel vaccines by Thomas, TM, Hodgson, SH, Emary, K, Patrick-Smith, M, Te Water Naude, R, Stuart, ASV, Henry, J, English, M, Moore, M, Douglas, N, Pollard, AJ, Vanderslott, S

“…In early 2020, adult volunteers were invited to participate in a first-in-human trial of the COVID-19 vaccine, ChAdOx1 nCoV-19, in the United Kingdom (UK) at the height of the global pandemic when there was uncertainty regarding vaccine efficacy and side-effects. …”

Accelerating typhoid conjugate vaccine introduction: what can be learned from prior new vaccine introduction initiatives? by Jamka, LP, Simiyu, KW, Bentsi-Enchill, AD, Mwisongo, AJ, Matzger, H, Marfin, AA, Pollard, AJ, Neuzil, KM

“…The health consequences of typhoid, including increasing prevalence of drug-resistant strains, can stress healthcare systems. While vaccination is one of the most successful and cost-effective health interventions, vaccine introduction can take years and require considerable effort. …”

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens by Moore, SC, Kronsteiner, B, Longet, S, Adele, S, Deeks, AS, Liu, C, Dejnirattisai, W, Reyes, LS, Meardon, N, Faustini, S, Al-Taei, S, Tipton, T, Hering, LM, Angyal, A, Brown, R, Nicols, AR, Dobson, SL, Supasa, P, Tuekprakhon, A, Cross, A, Tyerman, JK, Hornsby, H, Grouneva, I, Plowright, M, Zhang, P, Newman, TAH, Nell, JM, Abraham, P, Ali, M, Malone, T, Neale, I, Phillips, E, Wilson, JD, Murray, SM, Zewdie, M, Shields, A, Horner, EC, Booth, LH, Stafford, L, Bibi, S, Wootton, DG, Mentzer, AJ, Conlon, CP, Jeffery, K, Matthews, PC, Pollard, AJ, Brown, A, Rowland-Jones, SL, Mongkolsapaya, J, Payne, RP, Lambe, T, Screaton, G, Carroll, M, Klenerman, P, Dunachie, S

“…<p><strong>Background:</strong> Both infection and vaccination, alone or in combination, generate antibody and T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). …”

Injection fears and COVID-19 vaccine hesitancy by Freeman, D, Lambe, S, Yu, L-M, Freeman, J, Chadwick, A, Vaccari, C, Waite, F, Rosebrock, L, Petit, A, Vanderslott, S, Lewandowsky, S, Larkin, M, Innocenti, S, McShane, H, Pollard, AJ, Loe, BS

“…<p><strong>Background</strong></p> When vaccination depends on injection, it is plausible that the blood-injection-injury cluster of fears may contribute to hesitancy. …”

Herd immunity and vaccination of children for COVID-19 by Velavan, TP, Pollard, AJ, Kremsner, PG

Addressing vaccine inequities among Ukrainian refugees by Hill, M, Vanderslott, S, Volokha, A, Pollard, AJ

Recent advances in lipopolysaccharide-based glycoconjugate vaccines by Zhu, H, Rollier, CS, Pollard, AJ

“…However, because of the toxic lipid A moiety and relatively high costs of O-SP isolation, LPS has not been a popular vaccine antigen until recently. <br> <strong>Areas covered</strong> In this review, we discuss the rationales for developing LPS-based glycoconjugate vaccines, principles of glycoconjugate-induced immunity, and highlight the recent developments and challenges faced by LPS-based glycoconjugate vaccines. …”

Should children be vaccinated against COVID-19? by Zimmermann, P, Pittet, LF, Finn, A, Pollard, AJ, Curtis, N

“…Whether all children under 12 years of age should be vaccinated against COVID-19 remains an ongoing debate. …”

Assessment of vaccine herd protection in a cluster-randomised trial of Vi conjugate vaccine against typhoid fever: results of further analysis by Khanam, F, Kim, DR, Liu, X, Voysey, M, Pitzer, VE, Zaman, K, Pollard, AJ, Qadri, F, Clemens, JD

“…<p><strong>Background:&nbsp;</strong>A cluster-randomised trial of Vi-tetanus toxoid (Vi-TT) conjugate vaccine conducted in urban Bangladeshi children found a high level of direct protection by Vi-TT but no significant vaccine herd protection. …”